Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.
The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 24, 25 | -0.33 Increased by +8.33% | -0.29 Decreased by -12.51% |
| Nov 11, 24 | -0.25 Increased by +41.86% | -0.26 Increased by +3.85% |
| Aug 12, 24 | -0.23 Increased by +51.06% | -0.23 |
| May 13, 24 | -0.21 Increased by +59.62% | -0.34 Increased by +38.24% |
| Mar 26, 24 | -0.36 Increased by +25.00% | -0.44 Increased by +18.18% |
| Nov 13, 23 | -0.43 Increased by +15.69% | -0.50 Increased by +14.00% |
| Aug 7, 23 | -0.47 Increased by +51.04% | -0.54 Increased by +12.96% |
| May 8, 23 | -0.52 Increased by +43.48% | -0.52 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -48.59 M Decreased by -74.21% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -34.82 M Decreased by -7.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -29.61 M Increased by +15.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -25.18 M Increased by +29.23% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.87 M Increased by +N/A% | -27.89 M Increased by +13.03% | Decreased by -573.18% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -32.48 M Increased by +4.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -35.19 M Increased by +4.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -35.57 M Decreased by -0.72% | Decreased by N/A% Decreased by N/A% |